Found 19 matching trials
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease PHASE2 Study to evaluate the safety, tolerability, and pharmacodynamics of migalas...
Show More Location
Multiple Locations
Learn More & Join Trial
A Study of Patients With Fabry Disease (US Specific) N/A This is an observational study to evaluate the effects of treatment on long...
Show More Location
UAB Nephrology Research Clinic at Paula Building
Learn More & Join Trial
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease PHASE2 Study to evaluate the safety, tolerability, and pharmacodynamics of migalas...
Show More Location
Multiple Locations
Learn More & Join Trial
A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease PHASE2 Study to evaluate the safety, tolerability, and pharmacodynamics of migalas...
Show More Location
Multiple Locations
Learn More & Join Trial
Open-Label Phase 3 Long-Term Safety Study of Migalastat PHASE3 This was a long-term, open-label study of migalastat (123 milligrams \[mg\]...
Show More Location
Multiple Locations
Learn More & Join Trial
Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease N/A This program allows physicians to request permission from Amicus Therapeuti...
Show More Location
Multiple Locations
Learn More & Join Trial
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease PHASE3 This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynam...
Show More Location
University of South Florida
Learn More & Join Trial
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects PHASE1 GR181413A/AT1001 (migalastat hydrochloride) is a low molecular weight imino...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease PHASE3 The primary objective of this study was to compare the effect of migalastat...
Show More Location
Multiple Locations
Learn More & Join Trial
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) PHASE3 This was an open-label study to evaluate the safety, pharmacokinetics (PK),...
Show More Location
Clinical Study Site
Learn More & Join Trial